Hologic, Inc. $HOLX Holdings Increased by NEOS Investment Management LLC

NEOS Investment Management LLC boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 46.6% in the third quarter, HoldingsChannel.com reports. The firm owned 25,298 shares of the medical equipment provider’s stock after purchasing an additional 8,046 shares during the quarter. NEOS Investment Management LLC’s holdings in Hologic were worth $1,707,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares in the last quarter. Illinois Municipal Retirement Fund lifted its holdings in shares of Hologic by 20.4% in the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after purchasing an additional 29,143 shares in the last quarter. K.J. Harrison & Partners Inc acquired a new stake in shares of Hologic in the second quarter worth $1,987,000. New York State Common Retirement Fund grew its stake in Hologic by 16.3% during the 3rd quarter. New York State Common Retirement Fund now owns 142,622 shares of the medical equipment provider’s stock valued at $9,626,000 after acquiring an additional 20,000 shares in the last quarter. Finally, ING Groep NV purchased a new position in shares of Hologic during the 3rd quarter valued at $1,941,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

Hologic stock opened at $75.43 on Friday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $16.84 billion, a price-to-earnings ratio of 31.43, a P/E/G ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.47. The stock has a 50-day simple moving average of $74.92 and a 200 day simple moving average of $71.85.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.87 earnings per share. On average, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on HOLX shares. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research note on Friday, November 21st. Finally, Morgan Stanley raised their price objective on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.